Insider Buy: Diamedica Therapeutics
1:15PM ET 7/21/2022 MT NewswiresThomas Von Koch, 10% Owner, on July 08, 2022, executed a purchase for 207,974 shares in Diamedica Therapeutics (DMAC) for $275,898. Following the Form 4...
Quotes Snapshot > DMAC
DiaMedica Therapeutics Inc DMAC:NASDAQ
Last Price$1.97NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22
Today's Change+0.07(3.68%)
Bid (Size)$1.97 (2)
Ask (Size)$2.00 (12)
Day Low / High$1.88 - 1.98
Volume80.7 K
Read more news Recent News
Top Midday Decliners
2:14PM ET 7/07/2022 MT NewswiresDiaMedica Therapeutics (DMAC) said the US Food and Drug Administration placed a clinical hold on its phase 2/3 ReMEDy2 trial of its drug candidate DM199 to...
--Oppenheimer Downgrades DiaMedica Therapeutics to Market Perform From Outperform
12:56PM ET 7/07/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
--Lake Street Trims DiaMedica Therapeutics' Price Target to $8 From $14, Keeps Buy Rating
12:52PM ET 7/07/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call Transcript
12:01PM ET 8/11/2022 Seeking AlphaDiaMedica Therapeutics Inc. 2022 Q1 - Results - Earnings Call Presentation
10:19PM ET 5/15/2022 Seeking AlphaDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2022 Results - Earnings Call Transcript
9:09PM ET 5/06/2022 Seeking AlphaDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2021 Results - Earnings Call Transcript
12:20PM ET 3/15/2022 Seeking AlphaCompany Profile
Business DescriptionDiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN. View company web site for more details
| Address | 2 Carlson Parkway Minneapolis, Minnesota 55447 |
| Phone | +1.763.312.6755 |
| Number of Employees | 9 |
| President. Chief Executive Officer & Director | Rick John Pauls |
| Chief Financial Officer & Secretary | Scott Kellen |
| Chief Medical Officer | Kirsten Gruis |
| Chief Commercial Officer | Dominic Cundari |
Company Highlights
| Price Open | $1.89 |
| Previous Close | $1.90 |
| 52 Week Range | $1.15 - 4.82 |
| Market Capitalization | $52.1 M |
| Shares Outstanding | 26.4 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/09/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.56 |
| Beta vs. S&P 500 | N/A |
| Revenue | $500.0 K |
| Net Profit Margin | N/A |
| Return on Equity | -35.66% |
Analyst Ratings as of 07/06/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |